Seungbin Han

Universitätsklinikum Würzburg — Germany

Medicine · Health Sciences

7h-index177citations76works0.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Multiple Myeloma Research and Treatments(55), Protein Degradation and Inhibitors(30), Ubiquitin and proteasome pathways(21), Peptidase Inhibition and Analysis(8), Chronic Lymphocytic Leukemia Research(6)

Publications76 total

Single-molecule localization microscopy reveals the molecular organization of endogenous membrane receptors
Science Advances·2026Open Access
Promoter hypermethylation as a reversible mechanism of resistance to GPRC5D-directed therapy in multiple myeloma
Haematologica·2026Open Access
Toxoplasma gondii GRA2-Derived Peptides Mediated Apoptosis and Immune Clearance Overcome Drug Resistance via IFT22 Signaling in Lung Cancer
SSRN Electronic Journal·2026Open Access
Supplementary Table 3 from Single-Nucleotide Variants and Epimutations Induce Proteasome Inhibitor Resistance in Multiple Myeloma
2025Open Access
Supplementary Figure 4 from Single-Nucleotide Variants and Epimutations Induce Proteasome Inhibitor Resistance in Multiple Myeloma
2025Open Access
Supplementary Table 1 from Single-Nucleotide Variants and Epimutations Induce Proteasome Inhibitor Resistance in Multiple Myeloma
2025Open Access
Supplementary Figure 1 from Single-Nucleotide Variants and Epimutations Induce Proteasome Inhibitor Resistance in Multiple Myeloma
2025Open Access
Supplementary Figure 2 from Single-Nucleotide Variants and Epimutations Induce Proteasome Inhibitor Resistance in Multiple Myeloma
2025Open Access
Supplementary Table 4 from Single-Nucleotide Variants and Epimutations Induce Proteasome Inhibitor Resistance in Multiple Myeloma
2025Open Access
Supplementary Figure 3 from Single-Nucleotide Variants and Epimutations Induce Proteasome Inhibitor Resistance in Multiple Myeloma
2025Open Access
Supplementary Table 2 from Single-Nucleotide Variants and Epimutations Induce Proteasome Inhibitor Resistance in Multiple Myeloma
2025Open Access
Talquetamab alters T cell transcriptome in presence of GPRC5D on MM cells
Blood·2025
Lattice light-sheet microscopy reveals patient specific responses to CD20-directed antibodies in B cell malignancies
Blood·2025
Tumor intrinsic mechanisms leading to cevostamab resistance in multiple myeloma
Blood·2025Open Access
Modeling of a hyper-inflammatory hematopoietic niche ex vivo reveals a multi-step process driving CAR T- cell associated myeloid leukemia in multiple myeloma
Blood·2025Open Access
NQO1 modulates CD38 surface expression in multiple myeloma
Blood·2025
Impact of bortezomib on T-cell subsets and immune checkpoints under bispecific antibody therapy in multiple myeloma
Blood·2025Open Access
Upregulation of BCMA expression by selinexor
Blood·2025Open Access
Plasmapheresis facilitates soluble BCMA clearance and contributes to reversing primary resistance to anti-BCMA immunotherapy in multiple myeloma
Leukemia·2025· 3 citedOpen Access
Melphalan-Induced Enrichment of TP53-Mutant CHIP as a Risk Factor for Subsequent CAR-T Related Myeloid Neoplasms in Multiple Myeloma
Clinical Lymphoma Myeloma & Leukemia·2025
page 1 of 4Next →

Frequent Co-authors

Umair Munawar(48), Leo Rasche(45), Hermann Einsele(42), K. Martin Kortüm(40), Silvia Nerreter(40), Cornelia Vogt(38), Larissa Haertle(31), Eva Teufel(26), Xiang Zhou(24), Marietta Truger(24), Maximilian Steinhardt(24), Johannes M. Waldschmidt(24), Claudia Haferlach(22), Santiago Barrio(21), Joaquín Martínez‐López(21), Peter Raab(18), Thomas Haaf(17), Xiang Zhou(17), Andreas Rosenwald(16), Yanira Ruiz‐Heredia(15)